Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.62

+1.2%

1:43 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RXGOLF who wrote (15243)	2/18/1998 4:03:00 PM
From: Henry Niman	Read Replies (1) of 32384

Jesse Eisinger has an article on MRK (and PFE/MTC and LLY). The article notes that MRK is up, but questions if it should be based on deal between PFE and MTC's subsidiary, GD Searle. Agreement is for COX-2 (pain) medication for arthritis. Will compete with MRK and PFE's sale force should impact MRK, who also ran into competition previously when PFE marketed WLA's Lipitor for cholesterol. LLY is down because of Evista sales which may be bolstering MRK via competing Fosamax. However, article says two compounds may compete eventually, but now Fosamax is mainly used for treatment (in older women) while Evista is for prevention (younger women). CNBC just did a LLY/MRK/PFE story on similar topics.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next